Diabetes Resistance Training Adaptations in Elderly (DRTAE)
Muscle and Vascular Adaptations Induced by Resistance Training in Elderly Diabetic Type 2
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazil, 90035-903
- Hospital de Clinicas de Porto Alegre
-
Porto Alegre, Rio Grande do Sul, Brazil, 90690-000
- Federal University of Rio Grande do Sul, Physical Education School
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Type 2 diabetes
- 60 yers and older
- HbA1c > 6,5%
- BMI from 18,5 kg/m2 - 34,9 kg/m2
Exclusion Criteria:
- Current smoking
- Insulin users
- Hypertension uncontrolled
- Diabetic neuropathy
- Diabetic retinopathy
- Diabetic nephropathy
- Peripheral amputations
- Clinical depression
- Myocardial infarction (within past 6 months)
- Any unstable chronic condition
- Muscle-skeletal complications that limit the practice of the exercises
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Resistance training
Resistance training will be performed three times a week, for 12 weeks, composed by 12 resistance exercises for all body muscles with 2-3 series and 12-8 repetitions in each exercise.
|
The resistance training will be compound by 12 exercises for all body muscles, performed three times per week.
The intensity of training will be measure by maximum repetitions from 12 until 8 repetitions with 2-3 series.
The loads will increase for keep the maximum strength as the capacity of patients.
The blood pressure and the casual glycemic will be measure before and after the training in each session.
Before to start the exercises, patients will perform a warming on treadmill for 10 minutes and after the training will perform some stretching exercises for muscles groups trained.
|
|
Active Comparator: Stretching control
The control group will perform one stretching session a week.
|
The stretching session will be composed by stretching and joint mobilization exercises for all body muscles and will happen only one time per week.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Quadriceps Muscle Quality measure by echo intensity
Time Frame: 12 weeks
|
Echo intensity is a grey scale for analyse the image that ranging from 0 (black) to 255 (white).
|
12 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Functional capacity measure by stair climb test.
Time Frame: 12 weeks
|
Total time, as fast as possible, to climb 10 steps.
|
12 weeks
|
|
Quadriceps muscle strength measured by one repetition maximum (1RM) test.
Time Frame: 12 weeks
|
1RM is a maximum load lifted, reported in kg, during the knee extension.
|
12 weeks
|
|
Visceral adipose tissue measured by ultrasonography
Time Frame: 12 weks
|
Visceral adipose tissue (VAT) thickness measured by ultrasonography.
The VAT thickness is considered from the back of the subcutaneous tissue until the anterior part of the aorta.
It is reported in mm.
|
12 weks
|
|
Muscle thickness measured by ultrasonography
Time Frame: 12 weeks
|
Muscle thickness measured by ultrasonography takes into account the superior fascia of the muscle and the distance until the inferior fascia.
It is reported in mm.
|
12 weeks
|
|
Inflammation status estimated by tumor necrosis factor alpha (TNF-α ) and C reactive protein (CRP)
Time Frame: 12 weeks
|
TNF-α will be evaluated by specific commercial kit and CRP will be measured in a regular laboratorial equipment (COBAS C111).
|
12 weeks
|
|
Lipid profile
Time Frame: 12 weeks
|
HDL, LDL, total cholesterol and triglycerides will be measured in a regular laboratorial equipment (COBAS C111)
|
12 weeks
|
|
Glycemic profile
Time Frame: 12 weeks
|
Blood glycated hemoglobin and glucose will be measured in a regular laboratorial equipment (COBAS C111)
|
12 weeks
|
|
Endothelial function measured by ultrasonography
Time Frame: 12 weeks
|
Endothelial function estimated by the response of endothelial cells for hyperemia.
|
12 weeks
|
|
Quadriceps Muscle Quality measure by specific tension
Time Frame: 12 weeks
|
Specific tension is the ratio between muscle strength and muscle mass.
|
12 weeks
|
|
Functional capacity measure by time up and go test
Time Frame: 12 weeks
|
Time to get up from the chair walk around the marker (3 m) and return to the sitting position, as fast as possible.
|
12 weeks
|
|
Functional capacity measure by sit-to-stand-up test
Time Frame: 12 weeks
|
The time, as fast as possible, to stand and sit on the chair 10 times.
|
12 weeks
|
|
Quadriceps muscle power capacity measure by rate of torque development.
Time Frame: 12 weeks
|
The rate torque development is a slope of torque/time curve.
|
12 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Director: Alexandre S Dias, phd, Hospital de Clinicas de Porto Alegre
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 150257
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.